Disc Medicine (IRON) Income from Continuing Operations (2020 - 2026)
Disc Medicine (IRON) reported Income from Continuing Operations of 63453000.0 for Q1 2026, down 86.81% year-over-year from 481188791.69 in Q1 2025, and down 4.26% on a QoQ basis from 60860000.0 in Q4 2025.
Disc Medicine (IRON) has 7 years of Income from Continuing Operations data on file, last reported at 63453000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 86.81% year-over-year to 63453000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 241881000.0 (down 107.96% YoY) and the FY2025 annual result came in at 212513000.0, down 94.33% from the prior year.
- Income from Continuing Operations eased to 63453000.0 in Q1 2026 per IRON's latest filing, from 60860000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9580000.0 in Q2 2022 and bottomed at 63453000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 26287000.0 (2024), against an average of 29902470.59.
- Peak annual rise in Income from Continuing Operations reached 46.27% in 2022, while the deepest fall reached 161.83% in 2022.
- Tracing IRON's Income from Continuing Operations over 5 years: stood at 11244000.0 in 2022, then tumbled by 109.41% to 23546000.0 in 2023, then slipped by 25.1% to 29457000.0 in 2024, then plunged by 106.61% to 60860000.0 in 2025, then dropped by 4.26% to 63453000.0 in 2026.
- Per Business Quant, the three latest IRON Income from Continuing Operations figures stand at 63453000.0 (Q1 2026), 60860000.0 (Q4 2025), and 62321000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -63.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.45 Mn |
| Dec 31, 2025 | -60.86 Mn |
| Sep 30, 2025 | -62.32 Mn |
| Jun 30, 2025 | -55.25 Mn |
| Mar 31, 2025 | -33.97 Mn |
| Dec 31, 2024 | -29.46 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -26.29 Mn |
| Mar 31, 2024 | -26.95 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -14.10 Mn |
| Jun 30, 2023 | -15.95 Mn |
| Mar 31, 2023 | -22.78 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 18.19 Mn |
| Sep 30, 2021 | -18.45 Mn |
| Jun 30, 2021 | -16.44 Mn |
| Mar 31, 2021 | -18.34 Mn |
| Dec 31, 2020 | -812,495.00 |
| Sep 30, 2020 | -499,411.00 |
| Jun 30, 2020 | -6.77 Mn |
| Mar 31, 2020 | -9.75 Mn |